Indication

Transthyretin-related amyloid cardiomyopathy

Transthyretin-related amyloid cardiomyopathy (ATTR-CM) is a progressive, infiltrative myocardial disease caused by the extracellular accumulation of misfolded transthyretin protein fibrils within cardiac tissue. Read more about Transthyretin-related amyloid cardiomyopathy

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Transthyretin-related amyloid cardiomyopathy therapies.

Showing 1–3 of 3 drugs

VYNDAMAX (tafamidis)

AMYLOIDOSIS AGENTS - PROTEIN STABILIZERS·TRANSTHYRETIN-RELATED AMYLOID CARDIOMYOPATHY
Parke-Davis Pfizer

AMVUTTRA (vutrisiran sodium)

AMYLOIDOSIS AGENTS - TRANSTHYRETIN (TTR) SUPPRESSION·TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY·+1
ALNYLAM PHARMAC

ATTRUBY (acoramidis HCl)

AMYLOIDOSIS AGENTS - PROTEIN STABILIZERS·TRANSTHYRETIN-RELATED AMYLOID CARDIOMYOPATHY
BRIDGEBIO PHARM
Filter & compare in the drug finder →Opens the drug finder with Transthyretin-related amyloid cardiomyopathy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Transthyretin-related amyloid cardiomyopathy.

Transthyretin-related amyloid cardiomyopathy (ATTR-CM) is a progressive, infiltrative myocardial disease caused by the extracellular accumulation of misfolded transthyretin protein fibrils within cardiac tissue.

This condition primarily affects the cardiovascular system in older adults, occurring either as an age-related wild-type disorder or as an inherited form resulting from pathogenic *TTR* gene variants.

The amyloid deposition leads to biventricular wall thickening, increased myocardial stiffness, and impaired ventricular filling, typically manifesting as restrictive cardiomyopathy, progressive heart failure, and cardiac conduction abnormalities.

Personalize your experience

Follow Transthyretin-related amyloid cardiomyopathy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it